162 related articles for article (PubMed ID: 38110365)
21. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.
He J; Wu M; Xiong L; Gong Y; Yu R; Peng W; Li L; Li L; Tian S; Wang Y; Tao Q; Xiang T
Clin Epigenetics; 2020 Jun; 12(1):82. PubMed ID: 32517789
[TBL] [Abstract][Full Text] [Related]
22. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.
Mele L; la Noce M; Paino F; Regad T; Wagner S; Liccardo D; Papaccio G; Lombardi A; Caraglia M; Tirino V; Desiderio V; Papaccio F
J Exp Clin Cancer Res; 2019 Apr; 38(1):160. PubMed ID: 30987650
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
27. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
[TBL] [Abstract][Full Text] [Related]
28. The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer.
Wang C; Deng S; Chen J; Xu X; Hu X; Kong D; Liang G; Yuan X; Li Y; Wang X
Front Oncol; 2021; 11():616443. PubMed ID: 34094901
[TBL] [Abstract][Full Text] [Related]
29. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
30. Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.
Lian X; Zhu C; Lin H; Gao Z; Li G; Zhang N; Cao B; Kang Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32022229
[TBL] [Abstract][Full Text] [Related]
31. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
32. Pyrotinib shows a potent antitumor effect on HER2-positive esophageal cancer cells by promoting HER2 proteasomal degradation.
Zhao F; Zhu T; Zhao R; Liu J; Ren W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):191-196. PubMed ID: 38279442
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of pyrotinib and radiotherapy
Chen J; Zhang H; Zhou J; Wu Z; Wu X; Zhang S; Jiang Z; Wang T
Ann Transl Med; 2022 Nov; 10(22):1228. PubMed ID: 36544628
[TBL] [Abstract][Full Text] [Related]
34. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
35. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
Li J; Shui Z; Ouyang Q
Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
[TBL] [Abstract][Full Text] [Related]
36. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F; Yan M; Li W; Ouyang Q; Tong Z; Teng Y; Wang Y; Wang S; Geng C; Luo T; Zhong J; Zhang Q; Liu Q; Zeng X; Sun T; Mo Q; Liu H; Cheng Y; Cheng J; Wang X; Nie J; Yang J; Wu X; Wang X; Li H; Ye C; Dong F; Wu S; Zhu X; Xu B;
BMJ; 2023 Oct; 383():e076065. PubMed ID: 37907210
[TBL] [Abstract][Full Text] [Related]
37. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Liu D; Kou F; Gong J; Wang Z; Zhang X; Li J; Li Y; Li J; Zhou J; Lu M; Wang X; Lu Z; Cao Y; Zou J; Zhu X; Xu R; Shen L
Cancer Med; 2023 May; 12(9):10704-10714. PubMed ID: 37081722
[TBL] [Abstract][Full Text] [Related]
38. Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer.
Li Y; Ma X; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
Breast Cancer (Dove Med Press); 2022; 14():405-415. PubMed ID: 36510611
[TBL] [Abstract][Full Text] [Related]
39. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
[TBL] [Abstract][Full Text] [Related]
40. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
